The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), an annual meeting of American Society for Microbiology held in the early fall, is an interdisciplinary forum of international renown. ICAAC programs encourage the exchange of information among researchers and clinicians interested in antimicrobial and anticancer drugs and infectious diseases. Sessions are often developed in cooperation with other societies, domestic and international.

In addition to its scientific symposia, the conference includes special lectures, slide sessions and late-breaker slide sessions, poster presentations, state-of-the-art minilectures, meet-the-experts sessions, and interactive sessions that enable audience participation.

The American Society for Microbiology is the oldest and largest single life science membership organization in the world. The Society represents 24 disciplines of microbiological specialization plus a division for microbiology educators.

The following selected conference summaries are reported exclusively for The Body by Kenneth H. Mayer, M.D., Professor of Medicine and Community Health at Brown University, Director of the Brown University AIDS Program, and Chief of the Infectious Disease Division, Memorial Hospital of Rhode Island (Pawtucket), and Jim Thommes, M.D., Physician and Partner, Pacific Oaks Medical Group, Los Angeles, CA, Medical Director, Pacific Oaks Medical Group, and Clinical Instructor in Medicine, UCLA AIDS Care Center.

Funding for this conference coverage at The Body is provided, in part, through an unrestricted educational grant by Bristol-Myers Squibb Immunology.

Conference Summaries:

Friday, September 25, 1998

• I-57: Treatment of Primary HIV Infection with Zidovudine, Lamivudine and Indinavir: A Case-Control Study
  Coverage by Jim Thommes, M.D.
• I-79: Anti-Viral Activity and Resistance Profile of an HIV-1 Protease Inhibitor BMS-232632
  Coverage by Jim Thommes, M.D.
• I-84: Adefovir dipivoxil therapy significantly decreases HIV RNA in patients with high level AZT-3TC resistant HIV
  Coverage by Kenneth Mayer, M.D.
• I-88: Gemfibrozil effectively lowers protease-associated hypertriglyceridemia in HIV-infected patients
  Coverage by Kenneth Mayer, M.D.
• S-29: Issues in Salvage Therapy
  Coverage by Jim Thommes, M.D.

Saturday, September 26, 1998

• I-95: Incidence and factors associated with the development of hypercholesterolemia and hyperglycemia in HIV-infected patients using a protease inhibitor
  Coverage by Kenneth Mayer, M.D.
• I-97: d4T, ddI and nevirapine (NVP) in antiretroviral-naïve patients: a convenient triple regimen
  Coverage by Kenneth Mayer, M.D.
• I-108: A multicenter trial of adefovir when added to standard antiretroviral therapy
  Coverage by Kenneth Mayer, M.D.
• I-161: Experience of Health-Care Workers (HCWs) Taking Postexposure Prophylaxis (PEP) after Occupational HIV Exposures: Findings of the HIV PEP Registry
  Coverage by Jim Thommes, M.D.

Sunday, September 27, 1998

• I-200: Abacavir/efavirenz/adefovir salvage regimen for refractory HIV disease
  Coverage by Kenneth Mayer, M.D.
• O-21: Trends in Costs of Care for Patients with HIV
  Coverage by Jim Thommes, M.D.

Conference Reports and Related Articles:

• Antimicrobial Agents and Chemotherapy (December, 1998)
  Highlights from the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
  From Body Positive
• No News is Good News: Opportunistic Infections (November, 1998)
  Highlights from the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
  By Richard E. Chaisson, M.D. and William Bishai, M.D., Ph.D.
  From The Hopkins HIV Report
• Antiviral Therapy: How Simple Can You Get? (November, 1998)
  From Gay Men's Health Crisis (GMHC)
• Resistance Assay Update (October, 1998)
  From the Gay Men's Health Crisis (GMHC)